Accelerated drug approvals: The big questions facing payers
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Accelerated drug approvals: The big questions facing payers
-
ナレーター：
-
著者：
Dive into the latest episode of Pharmacy Friends for a discussion of the FDA Commissioner’s National Priority Voucher pilot. While accelerated approvals may improve access to innovative therapies, what could a compressed decision-making window mean for evidence review, affordability assessment and implementation planning?
Prime experts Angela Sutton and Bob Greer explore the important roles clinical confidence and operational readiness will play in making solid coverage decisions. Hear what they’re most focused on, including:
- Managing drug spend
- Assessing coverage strategies
- Determining policy risk
00:00 Introduction
02:10 What's generating all the questions now?
04:35 FDA Hearing
05:50 Pro's and con's of accelerated drug approvals
11:05 Policy uncertainty and impact to payers
11:54 Impact of FDA leadership changes
12:24 Meeting the moment
15:26 Using data to make better decisions that need to be fast
18:39 What we would tell the acting FDA leadership that matters
23:15 Closing